Skip to main content

People in the News: Feb 10, 2009

Premium

Gyros moved Erik Walldén into the CEO and president positions, after he had served over the past year as acting CEO. Walldén previously has been CEO of Affibody Holding, CEO of Biacore International and Pyrosequencing, and he is a non-executive director of Exiqon, Proxeon, and VisEn Medical.


Strategic Diagnostics has appointed Monette Greenway to be VP of marketing and sales, and Robert Laffer to be sales manager for life sciences. Greenway will take over a spot that was left behind by Fran DiNuzzo, who was appointed CEO in November.

Greenway formerly was president of the Integrated Technologies Division of Thermo Fisher Scientific, and she was a VP and GM at Invitrogen. Laffer previously was a regional sales manager at Panomics, and he was a global account executive for the BioPharma division of PerkinElmer’s Life and Analytical Sciences.


David Jorden has been named to the board of Cytomedix. He was most recently with Morgan Stanley's Private Wealth Management group where he was responsible for equity portfolio management for high net worth individuals. Prior to Morgan Stanley, Jorden served as chief financial officer for Genometrix.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.